Impact of stent deformity induced by the kissing balloon technique for bifurcating lesions on in-stent restenosis after coronary intervention

2018 ◽  
Vol 31 (4) ◽  
pp. 421-429
Author(s):  
Tadatsugu Gamou ◽  
Kenji Sakata ◽  
Hidenobu Terai ◽  
Yuki Horita ◽  
Masatoshi Ikeda ◽  
...  
Keyword(s):  
Coronary Intervention ◽  
Stent Restenosis ◽  
Kissing Balloon Technique ◽  
Balloon Technique ◽  
In Stent Restenosis

scholarly journals Clinical outcome of treatment with or without a final kissing balloon technique for bifurcation in-stent restenosis lesions

2017 ◽  
Vol 69 (6) ◽  
pp. 808-814
Author(s):  
Takayuki Yabe ◽  
Mikihoto Toda ◽  
Rine Nakanishi ◽  
Daiga Saito ◽  
Ippei Watanabe ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Stent Restenosis ◽  
Kissing Balloon Technique ◽  
Balloon Technique ◽  
In Stent Restenosis

Characteristics and Outcomes of Patients Undergoing Coronary Intervention for In-Stent Restenosis

2021 ◽  
Vol 28 ◽  
pp. S23-S24
Author(s):  
Chava Chezar-Azerrad ◽  
Charan Yerasi ◽  
Brian C. Case ◽  
Brian J. Forrestal ◽  
Giorgio A. Medranda ◽  
...  
Keyword(s):  
Coronary Intervention ◽  
Stent Restenosis ◽  
In Stent Restenosis

In vivo and in vitro analyses of the effects of a novel high-nitrogen low-nickel coronary stent on reducing in-stent restenosis

2018 ◽  
Vol 33 (1) ◽  
pp. 64-71 ◽  
Author(s):  
Jinpeng Wang ◽  
Chunli Song ◽  
Yanlong Xiao ◽  
Bin Liu
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Coronary Arteries ◽  
Coronary Intervention ◽  
Coronary Stent ◽  
High Nitrogen ◽  
Stent Restenosis ◽  
Percutaneous Coronary ◽  
In Stent Restenosis

Currently, percutaneous coronary intervention is an important treatment for coronary heart disease. However, the in-stent restenosis rate is still approximately 10–30% after stenting. Nickel ions from the stent are considered to be associated with in-stent restenosis. Therefore, in the present study, we quantitatively evaluated in-stent restenosis after implanting the novel high-nitrogen low-nickel coronary stent (HNS) and studied the mechanism underlying the reduction in in-stent restenosis by using ELISA and Western blot. The in vivo results showed that the HNS could significantly reduce neointima formation and inflammation as compared to SUS316L stents (316L) at 180 days after implantation in porcine coronary arteries and that vascular endothelial growth factor-A expression in porcine coronary arteries after HNS implantation also decreased. The in vitro results showed that, in the case of the HNS, human umbilical vein endothelial cell (HUVEC) proliferation was lower and lesser IL-6 release was noted from HUVECs at one and three days after culture than in the 316L group. Furthermore, p-STAT3 expression in HUVECs on the HNS surface was downregulated after culture for seven days. Thus, we conclude that the HNS could be a promising alternative coronary stent for percutaneous coronary intervention.

In-stent restenosis in the drug-eluting stent era

2018 ◽  
pp. 453-472
Author(s):  
Jaya Chandrasekhar ◽  
Adriano Caixeta ◽  
Philippe Généreux ◽  
George Dangas ◽  
Roxana Mehran
Keyword(s):  
Low Frequency ◽  
Bare Metal Stents ◽  
Coronary Intervention ◽  
Drug Eluting Stent ◽  
Metal Stents ◽  
Pharmacological Agents ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis

Since the inception of percutaneous coronary intervention, restenosis has been considered a significant problem. Although drug-eluting stents (DES) have reduced rates of in-stent restenosis (ISR) compared with bare metal stents across all lesion subsets, ISR has not been abolished. DES efficacy has been limited by suboptimal polymer biocompatibility, efficacy of pharmacological agents, in vivo pharmacokinetic properties, and local drug resistance and toxicity. While the first two DES to be manufactured (sirolimus- and paclitaxel-eluting stents) have the longest clinical follow-up, extensive data are now also available on zotarolimus- and everolimus-eluting stents. The uptake of biolimus-eluting stents has recently increased in clinical practice. Although the low frequency of DES ISR makes it difficult to investigate this condition fully, many studies have examined the mechanism, incidence, predictors, and optimal treatment of DES restenosis. This review discusses the data relevant to DES restenosis and the perspective on the current treatment of this condition.

scholarly journals Intracoronary lithotripsy for calcific neoatherosclerotic in-stent restenosis: a case report

2020 ◽  
Vol 4 (4) ◽  
pp. 1-4
Author(s):  
Helena Tizón-Marcos ◽  
Iris Rodríguez-Costoya ◽  
Cristina Tevar ◽  
Beatriz Vaquerizo
Keyword(s):  
Coronary Intervention ◽  
Percutaneous Treatment ◽  
Diabetic Woman ◽  
Intracoronary Imaging ◽  
Stent Restenosis ◽  
Promising Tool ◽  
Percutaneous Coronary ◽  
Calcific Plaque ◽  
St Elevation ◽  
In Stent Restenosis

Abstract Background In-stent restenosis is a difficult percutaneous scenario if calcific neoatherosclerosis is the underlying aetiology. Case summary A 69-year-old diabetic woman with a previous percutaneous coronary intervention on the left anterior descending coronary artery was readmitted for non-ST-elevation myocardial infarction. In-stent restenosis due to calcific neoatherosclerosis was observed by intracoronary imaging during the intervention. Intravascular lithotripsy was used successfully to fracture the underlying calcific plaque. However, the balloon ruptured during treatment although this did not damage the artery. Discussion Intravascular lithotripsy is a promising tool for the treatment of extremely calcified lesions including calcific neoatherosclerosis of in-stent restenosis. Balloon rupture is a complication of this new percutaneous treatment that has not previously been described.

Sign in / Sign up

Export Citation Format

Share Document